Alpharma has become the latest company in the USA to be grantedapproval to market a generic version of Elan's Zanaflex (tizanidine hydrochloride) for spasticity (see also Marketletter July 8). The generics firm has been given clearance to market both the 2mg and 4mg versions of the drug, which it hopes to launch "in the near future." Alpharma estimates that sales of the brand reached $150 million in 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze